Howard J Federoff

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6030272/publications.pdf

Version: 2024-02-01

211 papers	15,581 citations	17405 63 h-index	18606 119 g-index
213 all docs	213 docs citations	213 times ranked	19191 citing authors

#	Article	IF	Citations
1	A retrotransposon storm marks clinical phenoconversion to late-onset Alzheimerâ€™s disease. GeroScience, 2022, 44, 1525-1550.	2.1	12
2	Differential responses of AMD mitochondrial DNA haplogroups to PU-91, a mitochondria-targeting drug. Mitochondrion, 2021, 60, 189-200.	1.6	2
3	Plasma Sphingomyelins in Late-Onset Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2021, 83, 1161-1171.	1.2	9
4	Repairing the Parkinsonian Brain. Journal of Parkinson's Disease, 2021, 11, S123-S125.	1.5	1
5	Seeking progress in disease modification in Parkinson disease. Parkinsonism and Related Disorders, 2021, 90, 134-141.	1.1	9
6	TGFÎ² Drives Metabolic Perturbations during Epithelial Mesenchymal Transition in Pancreatic Cancer: TGFÎ² Induced EMT in PDAC. Cancers, 2021, 13, 6204.	1.7	8
7	Effect of earlyâ€stage Alzheimer's disease on household financial outcomes. Health Economics (United) Tj ETQq1 1 0.784314 rgBT /Ove	0.8	4
8	Association of plasma YKL-40 with brain amyloid-Î² levels, memory performance, and sex in subjective memory complainers. Neurobiology of Aging, 2020, 96, 22-32.	1.5	18
9	A Community-Based Study Identifying Metabolic Biomarkers of Mild Cognitive Impairment and Alzheimerâ€™s Disease Using Artificial Intelligence and Machine Learning. Journal of Alzheimer's Disease, 2020, 78, 1381-1392.	1.2	16
10	Blood Biomarkers of Cognitive Health and Neurodegenerative Disease. , 2020, , 568-586.		0
11	GDNF and Parkinsonâ€™s Disease: Where Next? A Summary from a Recent Workshop. Journal of Parkinson's Disease, 2020, 10, 875-891.	1.5	63
12	Trial of magnetic resonanceâ€“guided putaminal gene therapy for advanced Parkinson's disease. Movement Disorders, 2019, 34, 1073-1078.	2.2	65
13	PU-91 drug rescues human age-related macular degeneration RPE cells; implications for AMD therapeutics. Aging, 2019, 11, 6691-6713.	1.4	10
14	Precision pharmacology for Alzheimerâ€™s disease. Pharmacological Research, 2018, 130, 331-365.	3.1	79
15	Apolipoprotein E genotype impact on memory and attention in older persons: the moderating role of personality phenotype. International Journal of Geriatric Psychiatry, 2018, 33, 332-339.	1.3	5
16	Fetal Bovine Serum-Derived Extracellular Vesicles Persist within Vesicle-Depleted Culture Media. International Journal of Molecular Sciences, 2018, 19, 3538.	1.8	79
17	Toward Reproducible Results from Targeted Metabolomic Studies: Perspectives for Data Pre-processing and a Basis for Analytic Pipeline Development. Current Topics in Medicinal Chemistry, 2018, 18, 883-895.	1.0	16
18	Protect NIH's DNA advisory committee. Science, 2018, 362, 409-410.	6.0	2

#	Article	IF	Citations
19	Potential Metabolomic Linkage in Blood between Parkinsonâ€™s Disease and Traumatic Brain Injury. Metabolites, 2018, 8, 50.	1.3	14
20	Plasma metabolomic biomarkers accurately classify acute mild traumatic brain injury from controls. PLoS ONE, 2018, 13, e0195318.	1.1	30
21	Plasma microRNA markers of upper limb recovery following human stroke. Scientific Reports, 2018, 8, 12558.	1.6	17
22	Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models. Molecular Therapy, 2017, 25, 2231-2235.	3.7	49
23	Personality and Performance in Specific Neurocognitive Domains Among Older Persons. American Journal of Geriatric Psychiatry, 2017, 25, 900-908.	0.6	34
24	Biomarker validation: Methods and matrix matter. Alzheimer's and Dementia, 2017, 13, 608-609.	0.4	7
25	What success can teach us about failure: the plasma metabolome of older adults with superior memory and lessons for Alzheimer's disease. Neurobiology of Aging, 2017, 51, 148-155.	1.5	74
26	Systems healthcare: a holistic paradigm for tomorrow. BMC Systems Biology, 2017, 11, 142.	3.0	22
27	Targeting Microglial Activation States as a Therapeutic Avenue in Parkinsonâ€™s Disease. Frontiers in Aging Neuroscience, 2017, 9, 176.	1.7	245
28	Metabolomic biomarkers of pancreatic cancer: a meta-analysis study. Oncotarget, 2017, 8, 68899-68915.	0.8	55
29	INTRODUCTION: NEW INSIGHTS INTO LONG-STANDING ISSUES. Technology and Innovation, 2016, 17, 85-86.	0.2	0
30	Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimerâ€™s Disease. Frontiers in Neurology, 2015, 6, 237.	1.1	97
31	Critical periods after stroke study: translating animal stroke recovery experiments into a clinical trial. Frontiers in Human Neuroscience, 2015, 9, 231.	1.0	46
32	PGCâ^'1Î± Promoter Methylation in Parkinsonâ€™s Disease. PLoS ONE, 2015, 10, e0134087.	1.1	95
33	Perspectives on Best Practices for Gene Therapy Programs. Human Gene Therapy, 2015, 26, 127-133.	1.4	14
34	Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study. Lancet Neurology, The, 2015, 14, 1002-1009.	4.9	179
35	Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A caseâ€€control study. Alzheimer's and Dementia, 2015, 11, 600.	0.4	656
36	Modules, networks and systems medicine for understanding disease and aiding diagnosis. Genome Medicine, 2014, 6, 82.	3.6	169

#	Article	IF	Citations
37	Immune Responses in Parkinsonâ€™s Disease: Interplay between Central and Peripheral Immune Systems. BioMed Research International, 2014, 2014, 1-9.	0.9	91
38	The Evolution of Gene Transfer, Gene Therapy, and the RAC: IOM Recommendations to the NIH Director. Molecular Therapy, 2014, 22, 685-686.	3.7	2
39	Plasma phospholipids identify antecedent memory impairment in older adults. Nature Medicine, 2014, 20, 415-418.	15.2	885
40	Gene Therapy: Charting a Future Courseâ€"Summary of a National Institutes of Health Workshop, April 12, 2013. Human Gene Therapy, 2014, 25, 488-497.	1.4	12
41	The critical need for defining preclinical biomarkers in Alzheimer'sÂdisease. Alzheimer's and Dementia, 2014, 10, S196-212.	0.4	113
42	Microglial Activation and Antioxidant Responses Induced by the Parkinsonâ€™s Disease Protein Î±-Synuclein. Journal of NeuroImmune Pharmacology, 2013, 8, 94-117.	2.1	145
43	Development of Inducible Leucine-rich Repeat Kinase 2 (LRRK2) Cell Lines for Therapeutics Development in Parkinson's Disease. Neurotherapeutics, 2013, 10, 840-851.	2.1	4
44	Network modeling to identify new mechanisms and therapeutic targets for Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2013, 13, 685-693.	1.4	0
45	Single-Chain Fragment Variable Passive Immunotherapies for Neurodegenerative Diseases. International Journal of Molecular Sciences, 2013, 14, 19109-19127.	1.8	37
46	Social media communications networks and pharmacovigilance: SequelAE-2.0. , 2013, , .		1
47	Genomics and Bioinformatics of Parkinson's Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a009449-a009449.	2.9	24
48	EDITORIAL: PREFACE TO THE SPECIAL SECTION. Technology and Innovation, 2012, 14, 179-179.	0.2	0
49	EDITORIAL: TECHNOLOGY, INNOVATION, AND HEALTH. Technology and Innovation, 2012, 13, 261-262.	0.2	0
50	TECHNOLOGY AND INVENTION. Technology and Innovation, 2012, 14, 1-2.	0.2	0
51	Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurology, The, 2012, 11, 643-650.	4.9	46
52	Gene Therapy for the Treatment of Parkinsonâ€™s Disease: The Nature of the Biologics Expands the Future Indications. Pharmaceuticals, 2012, 5, 553-590.	1.7	7
53	Ectodomain shedding of nectinâ€1 regulates the maintenance of dendritic spine density. Journal of Neurochemistry, 2012, 120, 741-751.	2.1	21
54	EDITORIAL: THE INAUGURAL CONFERENCE OF THE NATIONAL ACADEMY OF INVENTORS. Technology and Innovation, 2012, 14, 219-220.	0.2	0

#	Article	IF	Citations
55	Trk retrograde signaling requires persistent, Pincher-directed endosomes. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 852-857.	3.3	61
56	Evaluation of an AAV2-Based Rapamycin-Regulated Glial Cell Line-Derived Neurotrophic Factor (GDNF) Expression Vector System. PLoS ONE, 2011, 6, e27728.	1.1	17
57	Article Commentary: Technology and Innovation: 2010 a Year in Review. Cell Transplantation, 2011, 20, 1315-1318.	1.2	0
58	Combined delivery of Nogo-A antibody, neurotrophin-3 and the NMDA-NR2d subunit establishes a functional â€˜detourâ€™ in the hemisected spinal cord. European Journal of Neuroscience, 2011, 34, 1256-1267.	1.2	58
59	Characterization of nectin processing mediated by presenilinâ€dependent gammaâ€secretase. Journal of Neurochemistry, 2011, 119, 945-956.	2.1	13
60	Membrane palmitoylated proteins regulate trafficking and processing of nectins. European Journal of Cell Biology, 2011, 90, 365-375.	1.6	21
61	Therapeutic potential of vaccines for Alzheimerâ€™s disease. Immunotherapy, 2011, 3, 287-298.	1.0	15
62	Interventional MRI-guided Putaminal Delivery of AAV2-GDNF for a Planned Clinical Trial in Parkinson's Disease. Molecular Therapy, 2011, 19, 1048-1057.	3.7	120
63	Disclosure of Clinical Trial Results When Product Development Is Abandoned. Science Translational Medicine, 2011, 3, 102cm29.	5.8	9
64	ANNOUNCING THE INAUGURAL ISSUE OF <I>TECHNOLOGY AND INNOVATION</I> (FORMERLY) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 3	0.2	1
65	Future directions for immune modulation in neurodegenerative disorders: focus on Parkinsonâ€™s disease. Journal of Neural Transmission, 2010, 117, 1019-1025.	1.4	34
66	An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies. Journal of Neuroscience Methods, 2010, 190, 171-179.	1.3	76
67	Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Medicine, 2010, 16, 998-1000.	15.2	342
68	Î±â€Synuclein mediates alterations in membrane conductance: a potential role for Î±â€synuclein oligomers in cell vulnerability. European Journal of Neuroscience, 2010, 32, 10-17.	1.2	65
69	A Neurotoxic Phosphoform of Elk-1 Associates with Inclusions from Multiple Neurodegenerative Diseases. PLoS ONE, 2010, 5, e9002.	1.1	26
70	A New Research and Development Policy Framework for the Biomedical Research Enterprise. JAMA - Journal of the American Medical Association, 2010, 304, 1003.	3.8	5
71	Activity-dependent Î±-Cleavage of Nectin-1 Is Mediated by A Disintegrin and Metalloprotease 10 (ADAM10). Journal of Biological Chemistry, 2010, 285, 22919-22926.	1.6	46
72	Regeneration of the MPTP-Lesioned Dopaminergic System after Convection-Enhanced Delivery of AAV2-GDNF. Journal of Neuroscience, 2010, 30, 9567-9577.	1.7	113

#	Article	IF	Citations
73	Multidisciplinary Approaches to Biomedical Researchâ€"Reply. JAMA - Journal of the American Medical Association, 2010, 304, 2243.	3.8	2
74	The Endoplasmic Reticulum Stress Response Factor CHOP-10 Protects against Hypoxia-induced Neuronal Death. Journal of Biological Chemistry, 2010, 285, 21329-21340.	1.6	52
75	AÎ²-directed Single-chain Antibody Delivery Via a Serotype-1 AAV Vector Improves Learning Behavior and Pathology in Alzheimer's Disease Mice. Molecular Therapy, 2010, 18, 1471-1481.	3.7	66
76	PGC-1 Î±, A Potential Therapeutic Target for Early Intervention in Parkinsonâ€™s Disease. Science Translational Medicine, 2010, 2, 52ra73.	5.8	691
77	Evolving From Reductionism to Holism. JAMA - Journal of the American Medical Association, 2009, 302, 994.	3.8	86
78	HUMMR, a hypoxia- and HIF-1Î±â€"inducible protein, alters mitochondrial distribution and transport. Journal of Cell Biology, 2009, 185, 1065-1081.	2.3	81
79	Effects of Herpes Simplex Virus Amplicon Transduction on Murine Dendritic Cells. Human Gene Therapy, 2009, 20, 442-452.	1.4	4
80	Safety Evaluation of AAV2-GDNF Gene Transfer into the Dopaminergic Nigrostriatal Pathway in Aged and Parkinsonian Rhesus Monkeys. Human Gene Therapy, 2009, 20, 1627-1640.	1.4	102
81	Clinically Relevant Effects of Convection-Enhanced Delivery of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Aged Rhesus Monkeys. Human Gene Therapy, 2009, 20, 497-510.	1.4	77
82	Drug discovery dilemma and Cura Quartet collaboration. Drug Discovery Today, 2009, 14, 1006-1010.	3.2	8
83	Expression pattern of NuIP gene in adult mouse brain. Brain Research, 2009, 1302, 42-53.	1.1	3
84	Development of vaccination approaches for the treatment of neurological diseases. Journal of Comparative Neurology, 2009, 515, 4-14.	0.9	12
85	Immune-Directed Gene Therapeutic Development for Alzheimerâ€™s, Prion, and Parkinsonâ€™s Diseases. Journal of NeuroImmune Pharmacology, 2009, 4, 298-308.	2.1	8
86	Mutant Î±-Synuclein Overexpression Mediates Early Proinflammatory Activity. Neurotoxicity Research, 2009, 16, 238-254.	1.3	130
87	Nur(R1)turing a Notion on the Etiopathogenesis of Parkinsonâ€™s Disease. Neurotoxicity Research, 2009, 16, 261-270.	1.3	10
88	Functional Effects of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Parkinsonian Rhesus Monkeys. Human Gene Therapy, 2009, 20, 511-518.	1.4	86
89	Immune Responses to Herpesviral Vectors. Human Gene Therapy, 2009, 20, 434-441.	1.4	9
90	Generating Differentially Targeted Amyloid-Î² Specific Intrabodies as a Passive Vaccination Strategy for Alzheimer's Disease. Molecular Therapy, 2009, 17, 2031-2040.	3.7	43

#	Article	IF	Citations
91	HSV ICP0 recruits USP7 to modulate TLR-mediated innate response. Blood, 2009, 113, 3264-3275.	0.6	126
92	Potential of Nurr1 interactions to disclose new Parkinsonâ€™s therapeutics. Future Neurology, 2009, 4, 161-165.	0.9	0
93	Augmentation of anti-tumor responses of adoptively transferred CD8+T cells in the lymphopenic setting by HSV amplicon transduction. Cancer Immunology, Immunotherapy, 2008, 57, 663-675.	2.0	3
94	Temporal and spatial localization of nectinâ€1 and lâ€afadin during synaptogenesis in hippocampal neurons. Journal of Comparative Neurology, 2008, 507, 1228-1244.	0.9	31
95	Loss of c/EBP-Î² activity promotes the adaptive to apoptotic switch in hypoxic cortical neurons. Molecular and Cellular Neurosciences, 2008, 38, 125-137.	1.0	27
96	Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium. Neurobiology of Aging, 2008, 29, 1631-1643.	1.5	23
97	Synuclein activates microglia in a model of Parkinson's disease. Neurobiology of Aging, 2008, 29, 1690-1701.	1.5	397
98	Chronic Neuron-Specific Tumor Necrosis Factor-Alpha Expression Enhances the Local Inflammatory Environment Ultimately Leading to Neuronal Death in 3xTg-AD Mice. American Journal of Pathology, 2008, 173, 1768-1782.	1.9	205
99	Human Interleukin-10 Gene Transfer Is Protective in a Rat Model of Parkinson's Disease. Molecular Therapy, 2008, 16, 1392-1399.	3.7	75
100	The Good, the Bad, and the Cell Type-Specific Roles of Hypoxia Inducible Factor-1Î± in Neurons and Astrocytes. Journal of Neuroscience, 2008, 28, 1988-1993.	1.7	154
101	CNS Delivery of Vectored Prion-specific Single-chain Antibodies Delays Disease Onset. Molecular Therapy, 2008, 16, 481-486.	3.7	60
102	Identification of a Novel Nurr1-Interacting Protein. Journal of Neuroscience, 2008, 28, 9277-9286.	1.7	13
103	Reduced Pathology and Improved Behavioral Performance in Alzheimer's Disease Mice Vaccinated With HSV Amplicons Expressing Amyloid-Î² and Interleukin-4. Molecular Therapy, 2008, 16, 845-853.	3.7	49
104	In Cultured Astrocytes, p53 and MDM2 Do Not Alter Hypoxia-inducible Factor-1Î± Function Regardless of the Presence of DNA Damage. Journal of Biological Chemistry, 2007, 282, 16187-16201.	1.6	25
105	Translational considerations for CNS gene therapy. Expert Opinion on Biological Therapy, 2007, 7, 305-318.	1.4	16
106	Neuronal Specificity of HSV/Sleeping Beauty Amplicon Transduction In Utero Is Driven Primarily by Tropism and Cell Type Composition. Molecular Therapy, 2007, 15, 1848-1855.	3.7	17
107	Adoptively Transferred Tumor-Specific T Cells StimulatedEx vivoUsing Herpes Simplex Virus Amplicons Encoding 4-1BBL Persist in the Host and Show Antitumor ActivityIn vivo. Cancer Research, 2007, 67, 10027-10037.	0.4	17
108	Reversal of Misfolding: Prion Disease Behavioral and Physiological Impairments Recover following Postnatal Neuronal Deletion of the PrP Gene. Neuron, 2007, 53, 315-317.	3.8	3

#	Article	IF	Citations
109	Proteolytic processing of proNGF is necessary for mature NGF regulated secretion from neurons. Biochemical and Biophysical Research Communications, 2007, 361, 599-604.	1.0	35
110	Wild-type and mutant Î±-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD. Experimental Neurology, 2007, 204, 421-432.	2.0	46
111	Spatial And Temporal Expression of Herpes Simplex Virus Type 1 Amplicon-Encoded Genes: Implications for Their Use As Immunization Vectors. Human Gene Therapy, 2007, 18, 93-105.	1.4	15
112	Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival. Brain Research, 2007, 1134, 33-44.	1.1	12
113	Alterations in striatal dopamine catabolism precede loss of substantia nigra neurons in a mouse model of juvenile neuronal ceroid lipofuscinosis. Brain Research, 2007, 1162, 98-112.	1.1	30
114	Infectivity of herpes simplex virus type-1 (HSV-1) amplicon vectors in dendritic cells is determined by the helper virus strain used for packaging. Journal of Virological Methods, 2007, 145, 37-46.	1.0	2
115	Regulation of TLR Signaling by USP7.. Blood, 2007, 110, 2300-2300.	0.6	0
116	Identification of human Î±-synuclein specific single chain antibodies. Biochemical and Biophysical Research Communications, 2006, 349, 1198-1205.	1.0	30
117	CNS Gene Therapy and a Nexus of Complexity: Systems and Biology at a Crossroads. Cell Transplantation, 2006, 15, 267-273.	1.2	12
118	Microarrays in Parkinsonâ€™s disease: A systematic approach. NeuroRx, 2006, 3, 319-326.	6.0	34
119	Systems biology: A primer. NeuroRx, 2006, 3, 293-294.	6.0	0
120	Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiology of Disease, 2006, 21, 305-313.	2.1	92
121	Visual deficits in a mouse model of Batten disease are the result of optic nerve degeneration and loss of dorsal lateral geniculate thalamic neurons. Neurobiology of Disease, 2006, 22, 284-293.	2.1	66
122	HSV Amplicons: Neuro Applications. Current Gene Therapy, 2006, 6, 337-350.	0.9	9
123	Neuronal Precursor-Restricted Transduction via in Utero CNS Gene Delivery of a Novel Bipartite HSV Amplicon/Transposase Hybrid Vector. Molecular Therapy, 2006, 13, 580-588.	3.7	57
124	HSV ICP0 Inhibits TLR-Mediated NF-ÎºB Response to TLR Signaling.. Blood, 2006, 108, 5487-5487.	0.6	0
125	Altered Gene Expression Profiles Reveal Similarities and Differences Between Parkinson Disease and Model Systems. Neuroscientist, 2005, 11, 539-549.	2.6	38
126	Human Dendritic Cells Transduced with Herpes Simplex Virus Amplicons Encoding Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Elicit Adaptive Immune Responses from Human Cells Engrafted into NOD/SCID Mice and Confer Partial Protection against HIV-1 Challenge. Journal of Virology, 2005, 79, 2124-2132.	1.5	44

#	Article	IF	Citations
127	Blockade of Gap Junctions In Vivo Provides Neuroprotection After Perinatal Global Ischemia. Stroke, 2005, 36, 2232-2237.	1.0	121
128	Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson's disease?. Molecular Brain Research, 2005, 134, 18-23.	2.5	100
129	Î²-hexosaminidase lentiviral vectors: transfer into the CNS via systemic administration. Molecular Brain Research, 2005, 133, 286-298.	2.5	36
130	HSV amplicon-mediated AÎ² vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiology of Aging, 2005, 26, 393-407.	1.5	44
131	Herpes Simplex Virus Amplicon Delivery of a Hypoxia-Inducible Soluble Vascular Endothelial Growth Factor Receptor (sFlk-1) Inhibits Angiogenesis and Tumor Growth in Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2005, 12, 1025-1036.	0.7	20
132	Immune Shaping and the Development of Alzheimer's Disease Vaccines. Science of Aging Knowledge Environment: SAGE KE, 2005, 2005, pe35-pe35.	0.9	5
133	HSV Encoded ICP-0 Inhibits TLR Signaling in CLL Cells by Targeting TRAF-6.. Blood, 2005, 106, 2953-2953.	0.6	0
134	The role of the THY1 gene in human ovarian cancer suppression based on transfection studies. Cancer Genetics and Cytogenetics, 2004, 149, 1-10.	1.0	42
135	Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma. Journal of Gastrointestinal Surgery, 2004, 8, 812-823.	0.9	11
136	Dysregulation of Gene Expression in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Mouse Substantia Nigra. Journal of Neuroscience, 2004, 24, 7445-7454.	1.7	98
137	Apoptosis-Inducing Factor Substitutes for Caspase Executioners in NMDA-Triggered Excitotoxic Neuronal Death. Journal of Neuroscience, 2004, 24, 10963-10973.	1.7	258
138	Utilizing Tumor Hypoxia to Enhance Oncolytic Viral Therapy in Colorectal Metastases. Annals of Surgery, 2004, 239, 892-902.	2.1	27
139	Viral Delivery of NR2D Subunits Reduces Mg2+ Block of NMDA Receptor and Restores NT-3-Induced Potentiation of AMPA-Kainate Responses in Maturing Rat Motoneurons. Journal of Neurophysiology, 2004, 92, 2394-2404.	0.9	34
140	HSV Amplicon Transduction Activates an Innate Immune Response in CLL B Cells;Implications for Immune Therapy and Vaccine Development.. Blood, 2004, 104, 2514-2514.	0.6	6
141	Endothelin-1 regulates cardiac sympathetic innervation in the rodent heart by controlling nerve growth factor expression. Journal of Clinical Investigation, 2004, 113, 876-884.	3.9	74
142	Safety of viral vectors for neurological gene therapies. Current Opinion in Molecular Therapeutics, 2004, 6, 473-81.	2.8	4
143	Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing. Nature Medicine, 2003, 9, 231-236.	15.2	99
144	Systemic FIV vector administration: transduction of CNS immune cells and Purkinje neurons. Molecular Brain Research, 2003, 119, 1-9.	2.5	7

#	Article	IF	Citations
145	Neurotrophin secretory pathways and synaptic plasticity. Neurobiology of Aging, 2003, 24, 1135-1145.	1.5	36
146	Helper-free HSV-1 amplicons elicit a markedly less robust innate immune response in the CNS. Molecular Therapy, 2003, 7, 218-227.	3.7	63
147	p75 Neurotrophin Receptor Protects Primary Cultures of Human Neurons against Extracellular Amyloid Î² Peptide Cytotoxicity. Journal of Neuroscience, 2003, 23, 7385-7394.	1.7	83
148	Convergent Pathobiologic Model of Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 991, 152-166.	1.8	46
149	Neurotrophin-3 Transduction Attenuates Cisplatin Spiral Ganglion Neuron Ototoxicity in the Cochlea. Molecular Therapy, 2002, 6, 12-18.	3.7	101
150	Glucocorticoid-Regulated VEGF Expression in Ischemic Skeletal Muscle. Molecular Therapy, 2002, 5, 300-306.	3.7	22
151	Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6216-6221.	3.3	167
152	Reporter Gene Transfer Induces Apoptosis in Primary Cortical Neurons. Molecular Therapy, 2002, 5, 723-730.	3.7	66
153	Expression of Human Immunodeficiency Virus Type 1 gp120 from Herpes Simplex Virus Type 1-Derived Amplicons Results in Potent, Specific, and Durable Cellular and Humoral Immune Responses. Journal of Virology, 2002, 76, 5565-5580.	1.5	60
154	Efficacy of Multiagent Herpes Simplex Virus Amplicon-Mediated Immunotherapy as Adjuvant Treatment for Experimental Hepatic Cancer. Annals of Surgery, 2002, 236, 337-343.	2.1	23
155	Behavioral and Neurochemical Effects of Wild-Type and Mutated Human Î±-Synuclein in Transgenic Mice. Experimental Neurology, 2002, 175, 35-48.	2.0	255
156	Mediation of Poly(ADP-Ribose) Polymerase-1-Dependent Cell Death by Apoptosis-Inducing Factor. Science, 2002, 297, 259-263.	6.0	1,671
157	Somatic mosaic approaches and the aging brain. Neurobiology of Aging, 2002, 23, 977-984.	1.5	0
158	HSV Amplicon-Mediated Delivery of LIGHT Enhances the Antigen-Presenting Capacity of Chronic Lymphocytic Leukemia. Molecular Therapy, 2002, 6, 455-463.	3.7	18
159	Comparison of safety, delivery, and efficacy of two oncolytic herpes viruses (G207 and NV1020) for peritoneal cancer. Cancer Gene Therapy, 2002, 9, 935-945.	2.2	89
160	Enhanced vascularization and survival of neural transplants with ex vivo angiogenic gene transfer. Cell Transplantation, 2002, 11, 331-49.	1.2	16
161	Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity. Cancer Research, 2002, 62, 6545-51.	0.4	22
162	Dendritic Cells Transduced with HSV-1 Amplicons Expressing Prostate-Specific Antigen Generate Antitumor Immunity in Mice. Human Gene Therapy, 2001, 12, 1867-1879.	1.4	50

#	Article	IF	Citations
163	Regulation of Neuronal Traits by a Novel Transcriptional Complex. Neuron, 2001, 31, 353-365.	3.8	400
164	Development of herpes simplex virus-1 ampliconâ€“based immunotherapy for chronic lymphocytic leukemia. Blood, 2001, 98, 287-295.	0.6	59
165	Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nature Medicine, 2001, 7, 859-863.	15.2	106
166	Modulation of the neuronal glutamate transporter EAAT4 by two interacting proteins. Nature, 2001, 410, 89-93.	13.7	234
167	Gene therapeutic approaches to the treatment of Parkinson's disease. Clinical Neuroscience Research, 2001, 1, 483-495.	0.8	7
168	HSV Amplicon-Mediated Neurotrophin-3 Expression Protects Murine Spiral Ganglion Neurons from Cisplatin-Induced Damage. Molecular Therapy, 2001, 3, 958-963.	3.7	78
169	Functional Interaction between Fluorodeoxyuridine-Induced Cellular Alterations and Replication of a Ribonucleotide Reductase-Negative Herpes Simplex Virus. Journal of Virology, 2001, 75, 7050-7058.	1.5	40
170	A Novel Approach to Cancer Therapy Using an Oncolytic Herpes Virus to Package Amplicons Containing Cytokine Genes. Molecular Therapy, 2001, 4, 250-256.	3.7	66
171	Intravesical oncolytic viral therapy using attenuated, replicationâ€competent, herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB Journal, 2001, 15, 1306-1308.	0.2	80
172	Neoadjuvant Interleukin-12 Immunogene Therapy Protects Against Cancer Recurrence After Liver Resection in an Animal Model. Annals of Surgery, 2000, 231, 762-771.	2.1	28
173	Efficient cotransduction of tumors by multiple herpes simplex vectors: Implications for tumor vaccine production. Cancer Gene Therapy, 2000, 7, 581-588.	2.2	15
174	Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. Journal of Molecular Medicine, 2000, 78, 166-174.	1.7	47
175	Enhanced Learning in Mice Parallels Vector-Mediated Nerve Growth Factor Expression in Hippocampus. Human Gene Therapy, 2000, 11, 2341-2352.	1.4	25
176	Overexpression of GluR6 in Rat Hippocampus Produces Seizures and Spontaneous Nonsynaptic Bursting in Vitro. Neurobiology of Disease, 2000, 7, 362-374.	2.1	44
177	Repeated Acquisition and Performance Chamber for Mice: A Paradigm for Assessment of Spatial Learning and Memory. Neurobiology of Learning and Memory, 2000, 74, 241-258.	1.0	23
178	Oncolytic viral therapy for human colorectal cancer and liver metastases using a multiâ€mutated herpes simplex virus typeâ€1 (G207). FASEB Journal, 1999, 13, 1325-1334.	0.2	165
179	Hypoxia-Inducible Factor-1Î± Mediates Hypoxia-Induced Delayed Neuronal Death That Involves p53. Journal of Neuroscience, 1999, 19, 6818-6824.	1.7	175
180	Selective Infection and Cytolysis of Human Head and Neck Squamous Cell Carcinoma with Sparing of Normal Mucosa by a Cytotoxic Herpes Simplex Virus Type 1 (G207). Human Gene Therapy, 1999, 10, 1599-1606.	1.4	86

#	Article	IF	Citations
181	Gene Therapy in the Inner Ear: Mechanisms and Clinical Implications. Annals of the New York Academy of Sciences, 1999, 884, 345-360.	1.8	31
182	In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors. Cancer Immunology, Immunotherapy, 1999, 47, 265-271.	2.0	19
183	An infectious conspiracy: the case for HSV-1 and APOEÏµ4 in Alzheimerâ€™s disease. Neurobiology of Aging, 1999, 20, 467-468.	1.5	2
184	Focal hippocampal gain of NGF function elicits specific septal cholinergic reorganization. NeuroReport, 1999, 10, 337-344.	0.6	6
185	Lentivirus Vectors Using Human and Simian Immunodeficiency Virus Elements. Journal of Virology, 1999, 73, 2832-2840.	1.5	103
186	Reproducible and efficient murine CNS gene delivery using a microprocessor-controlled injector. Journal of Neuroscience Methods, 1998, 80, 137-147.	1.3	38
187	Luciferase: a sensitive and quantitative probe for blood-brain barrier disruption. Journal of Neuroscience Methods, 1998, 83, 159-164.	1.3	6
188	Efficient gene transfer to human squamous cell carcinomas by the herpes simplex virus type 1 amplicon vector. American Journal of Surgery, 1998, 176, 404-408.	0.9	19
189	Topical Application of Viral Vectors for Epidermal Gene Transfer. Journal of Investigative Dermatology, 1997, 108, 803-808.	0.3	75
190	Nerve growth factor somatic mosaicism produced by herpes virus-directed expression of ere recombinase. Nature Biotechnology, 1997, 15, 57-62.	9.4	43
191	Use of the herpes amplicon system as a vehicle for somatic gene transfer. Advanced Drug Delivery Reviews, 1997, 27, 29-39.	6.6	5
192	Somatic gene transfer approaches to manipulate neural networks. Journal of Neuroscience Methods, 1997, 71, 133-142.	1.3	15
193	Regulated Release and Polarized Localization of Brain-Derived Neurotrophic Factor in Hippocampal Neurons. Molecular and Cellular Neurosciences, 1996, 7, 222-238.	1.0	319
194	ProlongedIn VivoGene Expression Driven by a Tyrosine Hydroxylase Promoter in a Defective Herpes Simplex Virus Amplicon Vector. Human Gene Therapy, 1996, 7, 2015-2024.	1.4	91
195	Rapid Production of Interleukin-2-Secreting Tumor Cells by Herpes Simplex Virus-Mediated Gene Transfer: Implications for Autologous Vaccine Production. Human Gene Therapy, 1996, 7, 2217-2224.	1.4	50
196	Expression of thebcl-2Gene from a Defective HSV-1 Amplicon Vector Protects PancreaticÎ²-Cells from Apoptosis. Human Gene Therapy, 1996, 7, 1719-1726.	1.4	69
197	Herpes Simplex Virus Type 1 Amplicon Vectors with Glucocorticoid-Inducible Gene Expression. Human Gene Therapy, 1995, 6, 419-428.	1.4	61
198	A role for mossy fiber activation in the loss of CA3 and hilar neurons induced by transduction of the GluR6 kainate receptor subunit. Neuroscience Letters, 1995, 191, 67-70.	1.0	8

#	Article	IF	Citations
199	Overexpression of NGF within the Heart of Transgenic Mice Causes Hyperinnervation, Cardiac Enlargement, and Hyperplasia of Ectopic Cells. Developmental Biology, 1995, 169, 309-321.	0.9	142
200	Temporal pattern of internucleosomal DNA fragmentation in the striatum and hippocampus after transient forebrain ischemia. Neuroscience Letters, 1995, 186, 157-160.	1.0	34
201	Expression of Vascular Endothelial Growth Factor From a Defective Herpes Simplex Virus Type 1 Amplicon Vector Induces Angiogenesis in Mice. Circulation Research, 1995, 76, 161-167.	2.0	68
202	Expression of bcl-2 From a Defective Herpes Simplex Virusâ€“1 Vector Limits Neuronal Death in Focal Cerebral Ischemia. Stroke, 1995, 26, 1670-1675.	1.0	268
203	Transfer of the nerve growth factor gene into cell lines and cultured neurons using a defective Herpes Simplex virus vector. Transfer of the NGF gene into cells by a HSV-1 vector. Molecular Brain Research, 1994, 24, 327-335.	2.5	60
204	Viral Transduction of trkA into Cultured Nodose and Spinal Motor Neurons Conveys NGF Responsiveness. Developmental Biology, 1994, 163, 152-161.	0.9	41
205	Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Research, 1994, 634, 7-12.	1.1	289
206	Functional characterization of the rat GAP-43 promoter. Brain Research, 1994, 638, 211-220.	1.1	29
207	Localized gene transfer into organotypic hippocampal slice cultures and acute hippocampal slices. Journal of Neuroscience Methods, 1993, 50, 341-351.	1.3	51
208	Ontogeny, sex dimorphism, and neonatal sex hormone determination of synapse-associated messenger RNAs in rat brain. Molecular Brain Research, 1993, 20, 101-110.	2.5	47
209	Estrogenic regulation and sex dimorphism of growth-associated protein 43 kDa (GAP-43) messenger RNA in the rat. Molecular Brain Research, 1991, 11, 125-132.	2.5	65
210	Cloning and Characterization of the Rat Gene Encoding GAP-43. European Journal of Neuroscience, 1990, 2, 822-827.	1.2	40
211	GAP-43 gene expression during development: persistence in a distinctive set of neurons in the mature central nervous system. Developmental Brain Research, 1989, 46, 161-168.	2.1	177